Correlation Engine 2.0
Clear Search sequence regions


  • ataxia (6)
  • behavior (1)
  • biogenesis (2)
  • cerebellar ataxia (1)
  • curcumin (4)
  • fibroin (3)
  • friedreich ataxia (2)
  • FXN (3)
  • heart (1)
  • humans (1)
  • impairs (1)
  • mice (2)
  • patients (1)
  • silk (1)
  • sulfur (2)
  • Sizes of these terms reflect their relevance to your search.

    Abnormal iron metabolism, mitochondrial dysfunction and the derived oxidative damage are the main pathogeneses of Friedrich's ataxia (FRDA), a single-gene inherited recessive neurodegenerative disease characterized by progressive cerebellar and sensory ataxia. This disease is caused by frataxin (FXN) mutation, which reduces FXN expression and impairs iron sulfur cluster biogenesis. To date, there is no effective therapy to treat this condition. Curcumin is proposed harboring excellent ability to resist oxidative stress through Nrf2 activation and its newly found ability to chelate iron. However, its limitation is its poor water solubility and permeability. Here, we synthesized slow-release nanoparticles (NPs) by loading curcumin (Cur) into silk fibroin (SF) to form NPs with an average size of 150 nm (Cur@SF NPs), which exhibited satisfactory therapeutic effects on the improvement of FRDA manifestation in lymphoblasts (1 μM) derived from FRDA patients and in YG8R mice (150 mg/kg/5 days). Cur@SF NPs not only removed iron from the heart and diminished oxidative stress in general but also potentiate iron-sulfur cluster biogenesis, which compensates FXN deficiency to improve the morphology and function of mitochondria. Cur@SF NPs showed a significant advantage in neuron and myocardial function, thereby improving FRDA mouse behavior scores. These data encourage us to propose that Cur@SF NPs are a promising therapeutic compound in the application of FRDA disease. © 2022. The Author(s).

    Citation

    Li Xu, Zichen Sun, Zhiyao Xing, Yutong Liu, Hongting Zhao, Zhongmin Tang, Yu Luo, Shuangying Hao, Kuanyu Li. Cur@SF NPs alleviate Friedreich's ataxia in a mouse model through synergistic iron chelation and antioxidation. Journal of nanobiotechnology. 2022 Mar 09;20(1):118

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 35264205

    View Full Text